

Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office: S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones: ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail: info@indswiftlabs.com Website: www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2024

The President Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai 400 001 **Date: 28th June, 2024**

The Vice President, Listing Compliance Department, National Stock Exchange of India Limited, Exchange Plaza, 5th Floor Plot No. C/2, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051

ISIN: INE915B01019, INE915B07024 BSE Scrip Code: 532305, 957989

NSE Symbol: INDSWFTLAB

Subject: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulation")- Outcome of the Meeting of the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited ("the Company").

Reference: Outcome of Board meeting dated June 27, 2024

Dear Sir/ Madam,

This is in continuation to the outcome of the meeting of the Board of Directors held on Thursday, June 27, 2024, wherein the Board of Directors of the Company has approved the issuance and allotment of fully convertible warrants, to be convertible at an option of Warrant holder(s) in one or more tranches, within 18 (Eighteen) months from its allotment date into an equivalent number of fully paid-up equity shares of the face value of Rs.10 each/-, to the persons belonging to the "Promoter & Promoter Group" and "Non-Promoter Group" Category on preferential basis and approved the draft notice of Postal Ballot.

In this regard, we wish to inform you, that the Preferential Issue Committee of the Board of Directors of the Company, at their meeting held today i.e., Friday, June 28, 2024, has inter-alia, considered and approved the following:

- I. The approval of members shall be taken by way of an Extraordinary General Meeting ('EGM') instead by way of Postal Ballot, which is scheduled to be held on Monday, July 22, 2024 at 11:30 A.M. through VC/OAVM and approved the notice for the same and accordingly in terms of the provisions of Chapter V of the SEBI ICDR Regulations, the 'Relevant Date' for the purpose of determining the minimum issue price of the fully convertible warrants proposed to be issued to the proposed allottees shall be Friday, June 21, 2024.
- II. Accordingly, the issuance of up to 2,60,00,000 (Two Crores Sixty Lakhs) fully convertible warrants shall be made at an issue price of Rs. 121/- (Rupees One Hundred and Twenty-One Only) per warrant, for cash, for an aggregate amount of up to Rs. 3,14,60,00,000/- (Rupees





(A Recognised Export House)





Three Hundred Fourteen Crores and Sixty Lakh Only), to the below mentioned allottees ("Proposed Allottees"):

S. No.	Name of the Proposed Allottees	Category	No. of Warrants proposed to
			be issued and allotted (up to)
5.	Essix Biosciences Limited	Promoter & Promoter	80,00,000
		Group	
6.	HCP Investments		75,00,000
7.	Saral Incorporated VCC Sub Fund 1		65,00,000
8.	Zeal Global Opportunities Fund	Non- Promoter	40,00,000
TOTAL			2,60,00,000

The meeting commenced at 02:30 P.M. and concluded at 03:00 P.M.

CHANDIGAR

You are requested to kindly take the same on your records.

Thanking you,

Yours faithfully,

For IND-SWIFT LABORATORIES LTD

PARDEEP VERMA
VP-CORPORATE AFFAIRS
COMPANY SECRETARY